All the human being have the tendency to get any disease either it can be cure or not. One of the diseases that can kill a human in a slow progress is Alzheimer’s disease. This disease is a progressive degenerative disorder of the brain that affects memory loss and problem in thinking. Micheal et al (2010) reported that Alzheimer disease characterized by Alois Alzheimer in 1907 is a progressive degenerative disorder of the brain.Today, elder people tend to get this disease as their number of population increase. The cholinergic hypothesis, impairment of the cholinergic function give the critical affect in Alzheimer’s Disease especially in brain areas, dealing with memory, learning, behavior and emotional respond.
After a few past years the researchers doing many experiments to cure the Alzheimer’s disease, they successfully found a drug which can help to increase acetylcholine levels which is desirable for Alzheimer’s disease. The drug is known as galanthamine or Razadyne. Ping Jia et al (2008) stated that among all the acetylcholinesterase (AChE) inhibitors in a clinic, galanthamine exhibits unique dual mechanism on cholinergic system, not only inhibiting the cholinergic activity but also allosterically modulating nicotinic acetylcholinereceptors (AChER) which will promote the release of acetylcholine. Besides, it is less toxicity compared to tacrine, rivastigmine and donepezil. During the past few years, various galanthamine derivatives have been synthesized and tested for anticholinesterase activity, structure-activity-relationship (SAR) studies reveal that substitution of the nitrogen atom of galanthamine is favourable AChE inhibitory activity because show interaction with a peripharal anionic site (PAS).